NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/04/2024
Voltar para busca
Dado oficial do USPTO
ADTHERA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
23/04/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
9, 40, 42
Data de depósito
05/07/2022
Data de registro
23/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/04/2024
Última transação
23/04/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
24
Localização do titular
LONDON, GB
Examinador
CANFIELD III, JOSEPH
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ADTHERA BIO LIMITED
Delin Ventures Advisors Limited
Representantes
Jonathan A. Menkes KNOBBE, MARTENS, OLSON & BEAR, LLP
Classificação técnica
Classes Nice
Classe 9Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Downloadable software and software applications used to deliver information and content regarding advanced therapy medicinal products (ATMPs)cell and gene therapy products and services; downloadable software and software applications for use in pharmaceutical manufacturingdrug developmentdelivery of therapies to patients in the fields of advanced therapy medicinal productscell therapy and gene therapy
Classe 40
Cell culturecell therapy and gene therapy manufacturing services for others; manufacturing of advanced therapy medicinal products (ATMPs) for others; custom manufacture of therapeutic drugsmedicinescell therapies and gene therapies for others; custom manufacture of cell culture products for others; rental and leasing of cell culturecell therapy and gene therapy manufacturing apparatus; informationadvice and consultancy in relation to all the aforesaid
Classe 42
Biotechnology research; design and development of pharmaceutical products in the field of biotechnology; scientific research for medical purposes in the field of cell culturecell therapy and gene therapy; scientific research consultancy in relation to cell culturecell therapygene therapy manufacturing; development of cell culturecell therapy and gene therapy processes for others; scientific research in the nature of conducting clinical trials for others in the field of cell culturecell therapy and gene therapy services; scientific research in the nature of conducting clinical trials for others; pharmaceutical drug development services; rental of scientific apparatus and instruments; development of processes for cell culturecell therapy and gene therapy pharmaceutical manufacturing; development of processes for manufacturing of advanced therapy medicinal products; design and development of scientific cell culturecell therapy and gene therapy equipment and apparatus; design and development of scientific advanced therapy medicinal productspharmaceutical manufacturing equipment and apparatus; software as a service (SaaS) featuring software for pharmaceutical manufacturing and drug development in the field of advanced therapy medicinal productscell therapygene therapy and cell culture; providing temporary use ofonline non-downloadable software and online non-downloadable software platforms for pharmaceutical manufacturing and drug development in the field of advanced therapy medicinal productscell therapygene therapy and cell culture; software as a service (SaaS) featuring software for reviewingpurchasingorderingtrackingdeliveringmonitoring and analysing advanced therapy medicinal productscell therapygene therapy and cell culture products and services; platform as a service featuring computer software platforms for reviewingpurchasingorderingtrackingdeliveringmonitoring and analysing advanced therapy medicinal productscell therapygene therapy and cell culture products and services; providing temporary use of online non-downloadable software and online non-downloadable software platforms for reviewingpurchasingorderingtrackingdeliveringmonitoring and analysing advanced therapy medicinal productscell therapygene therapy and cell culture products and services; providing informationadvice and consultancy in relation to all the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
23/04/2024
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
17/03/2024
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
05/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/11/2023
PUBO
PUBLISHED FOR OPPOSITION
07/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/10/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
03/10/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
29/09/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/09/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
30/08/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/08/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
30/08/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/08/2023
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
09/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/08/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/05/2023
GNRT
NON-FINAL ACTION E-MAILED
02/05/2023
CNRT
NON-FINAL ACTION WRITTEN
02/05/2023
DOCK
ASSIGNED TO EXAMINER
18/04/2023
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
15/08/2022
ALIE
ASSIGNED TO LIE
15/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/07/2022
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/07/2022
NWAP
NEW APPLICATION ENTERED
08/07/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ADTHERA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.